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heimer’s Disease (AD). These trials aimed at evaluating the 
efficacy and safety of the combination of galantamine and 
memantine versus galantamine alone.  Results: Here, we re-
port on the scope and projects of the DCN, the methods that 
were employed, the composition and flow within the di-
verse groups of patients and control persons and on the clin-
ical and neuropsychological baseline characteristics of the 
group of 2,113 subjects who participated in the observation-
al and clinical trials.  Conclusion: These data have an impact 
on the procedures for the early and differential clinical diag-
nosis of dementias, the current standard treatment of AD as 
well as on future clinical trials in AD. 
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 Abstract 
 Background: The German Dementia Competence Network 
(DCN) has established procedures for standardized multi-
center acquisition of clinical, biological and imaging data, for 
centralized data management, and for the evaluation of new 
treatments.  Methods: A longitudinal cohort study was set 
up for patients with mild cognitive impairment (MCI), pa-
tients with mild dementia and control subjects. The aims 
were to establish the diagnostic, differential diagnostic and 
prognostic power of a range of clinical, laboratory and imag-
ing methods. Furthermore, 2 clinical trials were conducted 
with patients suffering from MCI and mild to moderate Alz-
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 Introduction 
 Dementia is a major health problem in the elderly. All 
epidemiological studies have shown strong correlations 
between age and the incidence/prevalence of dementing 
diseases. During the last century alone, the German pop-
ulation has shown a staggering increase in its proportion 
of elderly citizens. While the number of persons over 65 
years of age has quadrupled from 3.2 to 12.9 million, the 
proportion of those older than 80 years has increased 
even more dramatically from 300,000 to 3.2 million  [1, 2] . 
The increasing prevalence of patients with dementia has 
a considerable economic impact. Forthcoming treatment 
interventions are most promising in modifying the dis-
ease course when they are offered at an early disease stage 
or as preventive treatment. This calls for improved early 
or even predictive diagnosis of the dementias.
 The transitional stage between ‘normal’ functional 
ability and a full-blown clinical picture of dementia is 
described as mild cognitive impairment (MCI). The term 
MCI refers to some lowering of cognitive function, from 
a formerly normal level towards a mildly impaired level. 
Many different underlying reasons and etiologies may 
evoke this decline, including not only Alzheimer’s dis-
ease (AD), but also vascular lesions, alcohol abuse, epi-
lepsy, depression and others. Patients with AD will pass 
through the MCI stage before presenting with AD de-
mentia, but not all patients presenting with clinical MCI 
suffer from underlying AD pathology  [3] . Population 
studies have demonstrated that 10–25% of the over 65 
year olds in western industrialized nations have MCI  [4–
6] . The mean prevalence of MCI is approximately 16%, 
and thus twice as high as the prevalence of dementia. This 
proportion is equivalent to more than 10 million MCI 
sufferers over 65 years old in the European Community.
 The German Dementia Competence Network (DCN) 
is a research platform of university departments that 
teamed up to perform long-term studies on dementia, in-
cluding cross-sectional and prospective longitudinal co-
hort studies and clinical trials. The DCN is striving for 
the development and application of new innovative tools 
in early dementia detection, early intervention, treatment 
and care of patients with dementia and with common 
preceding symptoms (MCI). We have focused on a set of 
diagnostic and therapeutic core questions with immedi-
ate clinical relevance: Is it possible to predict which peo-
ple with MCI will develop dementia in a given time pe-
riod? How can the differential diagnosis of dementia be 
improved in a clinical context? Can progression of MCI 
to dementia be prevented or delayed through administra-
tion of antidementia drugs? Can pharmacological treat-
ment of Alzheimer’s dementia be improved by combina-
tion therapy? The global objectives of the DCN were to 
build a horizontal network of research-oriented univer-
sity-based memory clinics; to define standards for re-
cruitment, recognition, assessment and treatment of MCI 
and dementia; to establish tissue and DNA banks; and to 
perform therapeutic studies in MCI and dementia.
 In order to deal with the research questions cited 
above, large-scale cross-sectional as well as prospective 
diagnostic, treatment and observational studies were im-
plemented, the results of which are stored in long-term 
data and biomaterial banks. The project has created an 
enormous bulk of data and biomaterials. The 7-year fund-
ing period was financed by the Federal Ministry of Re-
search and Education. On a separate cohort of patients, 
another independent branch of the DCN performed epi-
demiological studies, which are described elsewhere
 [5, 7] .
 After screening, assessment and diagnostic classifica-
tion, the patients described here were entered either into 
a long-term observational study (diagnostic and prog-
nostic study, DAP study) or into 1 of 2 clinical trials: the 
first investigating the efficacy of galantamine/meman-
tine combination therapy versus galantamine alone or 
versus placebo in MCI (MCI-COMBI study), and the sec-
ond investigating the efficacy of galantamine/meman-
tine combination therapy versus galantamine alone in 
AD (AD-COMBI study). In all studies, a large set of iden-
tical baseline variables were assessed. This article de-
scribes the design of the 3 studies and presents a sum-
mary of the baseline characteristics and cross-sectional 
results of all participants. More detailed results obtained 
at baseline, results obtained at follow-up and results of 
the clinical trials will be reported in future publications.
 Materials and Methods 
 Participating Centers  
 Figures 1 ,  2 and  table 1 give an overview of the nationwide co-
hort study. All subjects were investigated with standardized diag-
nostic and therapeutic procedures. Each of the 14 German spe-
cialist memory clinics of university hospitals ( table 1 ) is equipped 
with clinical and scientific expertise in the area of dementia re-
search, access to magnetic resonance imaging (MRI), the ability 
to run neuropsychological tests and to gather biological material 
and prepare it for shipment. All centers had significant practical 
experience in carrying out clinical research in this domain. Fur-
ther details are available at the DCN website (www.kompetenz-
netz-demenzen.de).
 Kornhuber et al.
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Patient and controls fulfil inclusion criteria for
DAP, MCI-COMBI or AD-COMBI studies 
Screening
MCI or dementia













Dementia n = 790
MCI n = 1,080
Control subjects n = 243
DAP study
n = 1,613
Dementia n = 557
MCI  n = 813
Healthy controls n = 201
Diseased controls n = 42
MCI-COMBI study
n = 243
MCI  n = 243
AD-COMBI study
n = 217
AD n = 215
Mixed AD/VD n = 2
Screening only
n = 40
Dementia n = 16
MCI n = 24
 Fig. 1. Study flow chart. 
 Fig. 2. Patient assignment. VD = Vascular 
dementia. 
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 Screening and Selection Procedure 
 Patients who sought evaluation at the participating memory 
clinics, who were at least 50 years old and in whom organic cog-
nitive impairment was suspected underwent a screening assess-
ment (following informed consent) that resulted in a clinical diag-
nosis.
If 1 of the following clinical diagnoses was made, patients were 
requested to enroll in 1 of the assigned studies: 
 – MCI, any subtype: DAP study or MCI-COMBI study; 
 – AD, mild stage: DAP study or AD-COMBI trial; 
 – AD, moderate stage and Mini-Mental-State Examination 
(MMSE) score  6 15: AD-COMBI trial only; 
 – any other dementia, mild stage only: DAP study only. 
 Furthermore, control subjects were recruited:
 – healthy control subjects: DAP study only, with follow-up as-
sessments; 
 – diseased control subjects: DAP study only, baseline assess-
ment only. 
 The following exclusion criteria were applied: substance abuse 
or dependence, insufficient German language skills, multimor-
bidity, comorbid condition with excess mortality, circumstances 
that make regular attendance at follow-up visits questionable and 
lack of an informant.
 Control subjects were recruited from inpatients at the partici-
pating centers (diseased control subjects) or were unpaid volun-
teers, e.g. spouses of patients (healthy control subjects). Inclusion 
and exclusion criteria are listed in  table 2 .
 Following screening, the study criteria were checked, a second 
informed consent for additional diagnostic procedures or par-
ticipation in treatment studies was signed and visit schedules were 
set up. Those patients who participated in the screening examina-
tion and received one of the relevant diagnoses, but declined par-
ticipation in any study, were kept in the database (screening-only 
patients). Patients having none of the previously listed diagnoses 
were not entered into the database (screening failures). In clinical 
trial patients, treatment was performed according to study proto-
cols. Standard medical treatment was initiated or recommended 
in the DAP study, in screening-only and in screening-failure pa-
tients.
 Many, but not all, patients who participated in the 2 drug trials 
were requested to give written consent for the acquisition of sec-
ond and third blood samples and MRI, over and above the regular 
follow-up examinations. This was conducted subject to the capac-
ity of the participating centers.
 Definition of Cases 
 The study was planned in 2001, funding was obtained for a 7-
year period and consistent diagnostic criteria were applied for the 
total recruitment period, which lasted from 2003 to 2007. All clin-
ical diagnoses of MCI and the different dementia subtypes were 
given following the published clinical research criteria at the time 
of study start.
 The diagnoses of MCI and dementia were made on the basis 
of clinical and neuropsychological data. A specific MMSE thresh-
old was not applied for diagnosis. The Clinical Dementia Rating 
(CDR) was applied and the overall score was determined central-
ly, using the Washington University CDR-assignment algorithm 
 [8] . However, this CDR score was not used as the principle crite-
rion for dementia. Discrepancies, therefore, exist between clinical 
and CDR ratings. In particular, a considerable subset of the pa-
Table 1. Distribution of the German multicenter DCN cohort by 








Hamburg 64 21 2 5 92
Berlin 172 28 62 2 264
Göttingen 168 9 6 0 183
Düsseldorf 143 29 6 7 185
Bonn 135 19 25 7 186
Leipzig 88 14 0 0 102
Frankfurt 94 11 6 2 113
Heidelberg 105 30 1 5 141
Homburg (Saar) 6 0 0 0 6
Mannheim 122 15 24 2 163
Erlangen 166 19 13 2 200
Freiburg 101 12 33 1 147
LMU Munich 157 22 26 0 205
TU Munich 92 14 13 7 126
Total 1,613 243 217 40 2,113
LMU = Ludwig Maximilian University; TU = Technical University.




– Minimum age 50 years
Exclusion criteria
– Relevant neurological diseases, e.g. Parkinson’s disease, 
stroke, brain tumor, neuroborreliosis, epilepsy/seizures, grade 
II–III craniocerebral injury, normal pressure hydrocephalus, 
hypoxemic brain damage (e.g. during surgery)
– Current alcohol abuse or known alcohol dependency or 
long-term intake of benzodiazepines at high doses
– Malignant disease with chemo- or radiotherapy




– Patients who have undergone medically indicated lumbar 
puncture, e.g. due to headaches, intervertebral disc disease, 
suspected chronic CNS disease (e.g. multiple sclerosis)
– Minimum age 50 years
Exclusion criteria
– Concern about or suspicion of a neurodegenerative disease 
(AD, FTD, Parkinson’s disease, etc.), acute inflammatory 
process or normal pressure hydrocephalus
– No MCI at baseline (CDR = 0), or all cognitive tests that are 
listed in the ‘syndrome diagnosis’ section are within the 
normal range
FTD = Frontotemporal dementia; CDR = Clinical Dementia 
Rating.
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tients in the DAP study (n = 253), who were clinically diagnosed 
as having dementia, had a CDR score of only 0.5 according to the 
centrally determined CDR algorithm (see ‘Discussion’).
 Diagnosis of MCI. The syndrome of MCI is heterogeneous 
with regard to etiology and clinical picture. Decline in memory 
prevails in most but not all cases. We intended to include a broad 
range of patients at risk of developing dementia. Therefore, in-
stead of the classical MCI definition, which calls for a confirmed 
deficit in memory with otherwise essentially normal cognitive 
abilities, a broader definition of MCI was used, the core features 
being complaints of cognitive deficit in daily living and objecti-
fied decline of cognitive abilities (more than 1 SD) in at least 1 of 
the following domains, as evidenced by standardized neuropsy-
chological tests: verbal learning and memory, nonverbal learning 
and memory, word fluency, naming, visuoconstruction, cognitive 
speed or executive function. Minor changes in complex activities 
of daily living (ADL) were tolerated, for example, handling of fi-
nancial affairs and orientation in unknown surroundings [total 
Bayer-ADL (B-ADL) score  ! 4].
 Based on the clinical presentation and on neuropsychological 
test results, MCI patients received an additional clinical label of 
‘MCI of AD type’, ‘MCI of mixed-dementia type’, ‘MCI of fronto-
temporal dementia (FTD) type’, ‘MCI of vascular dementia (VD) 
type’, etc., or ‘unclassified’, following the published research cri-
teria for the respective dementia diagnoses ( table 3 ), but not re-
quiring a dementia syndrome. Clinical diagnoses and assign-
ments of MCI subtypes were made by team conferences at the 
local study centers.
 Inclusion in the MCI-COMBI trial was not conditional on the 
label of ‘presumable pre-AD’, but on a syndrome which compris-
es cognitive decline in verbal learning and memory.
 Diagnosis of Mild Dementia. Decline of cognitive ability (at 
least 1 SD) from a previous level in at least 2 domains as evidenced 
by age-corrected standardized tests; impairment in ADL (B-ADL 
 1 6); changes in personality, drive, social behavior or control of 
emotion. These changes must have persisted for at least 3 months. 
No clouding of consciousness.
 Diagnosis of Specific Causes of Dementia. Internationally ac-
cepted criteria were used for the diagnosis of specific causes of 
dementia ( table 3 ).
 Objectives and Design of the Long-Term Observational Study 
 The principle criterion for inclusion in the DAP study was the 
presence of MCI or early dementia with an MMSE score of  6 20. 
The principle objectives of the DAP study were threefold: (1) ob-
servation of the course of a large cohort of MCI and early demen-
tia patients, (2) examination of the utility, or combined utility, of 
a spectrum of methods for early diagnosis, and (3) identification 
of an optimal set of clinical, laboratory and imaging data for the 
prognosis of conversion from MCI to dementia. The principle ex-
ternal criterion for diagnosis and conversion will be the diagnoses 
that are made at follow-up.
 With regard to (1), observation and multidimensional pheno-
typing was carried out, including demographic, medical, neuro-
psychological, resource utilization and other parameters. The re-
sultant database serves to describe baseline characteristics and 
progression of early dementia, differences between types of de-
mentia, rates of false and correct diagnoses, risk factors, neuro-
psychological profiles, etc.
 With regard to (2), early diagnosis, emphasis was placed on the 
diagnostic power of neurochemical cerebrospinal fluid (CSF) and 
serum parameters, including but not limited to amyloid peptides 
and tau proteins, of volumetric cerebral MRI and of magnetic 
resonance spectroscopy (MRS). Furthermore, the diagnostic val-
ue of certain functional and behavioral inventories will be as-
sessed.
 With regard to (3), conversion rates, delay of conversion from 
MCI to different types of dementia, and the slope of decline will 
be subjected to regression analyses with relevant baseline param-
eters as independent variables. The AD assessment scale cognitive 
subscale (ADAS-cog) and the Consortium to Establish a Registry 
for AD neuropsychological assessment scale test series were cho-
sen as principal measures of neuropsychological impairment, and 
the CDR and CDR sum-of-boxes serve as global rating scales for 
the severity of dementia.
Table 3. Diagnostic criteria for specific causes of dementia
Specific cause Criteria proposed by Reference No.
AD NINCDS-ADRDA probable AD 35
AD with cerebrovascular disease NINCDS-ADRDA possible AD 35
Cerebrovascular disease NINDS-AIREN 36
FTD Lund and Manchester groups 37
Lewy body disease Consortium on DLB 38
Parkinson’s disease dementia Gelb et al., 1999 38
Huntington’s disease Vonsattel and DiFiglia, 1998 39
Progressive supranuclear palsy Litvan, 1997 40
Corticobasal degeneration Litvan et al., 1999 41
NINCDS = National Institute of Neurological and Communicative Disorders and Stroke; ADRDA = Alz-
heimer’s Disease and Related Disorders Association; NINDS = National Institute of Neurological Disorders and 
Stroke; AIREN = Association Internationale pour la Recherche et l’Enseignement en Neurosciences.
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 Objectives and Design of the Clinical Trials 
 The MCI-COMBI study was designed to assess the efficacy 
and safety of a combination of the acetylcholinesterase inhibitor 
galantamine with the NMDA receptor antagonist memantine  [9, 
10] versus galantamine alone or versus placebo in MCI. This was 
a 3-armed, randomized, double-blind, double-dummy, placebo-
controlled, multicenter study. In total, 243 patients with MCI 
were randomized and treated according to the protocol. The prin-
ciple inclusion criterion was the syndrome of MCI, regardless of 
the presumed underlying etiology. Due to suspected adverse 
events in 2 independent studies of galantamine in MCI  [11] , one 
sponsor (Janssen-Cilag, High Wycombe, UK) suspended delivery 
of medication, which led to early termination of the MCI-COMBI 
trial. Accordingly, the statistical analysis plan had to be amended. 
However, the data that were gathered were analyzed and will be 
published together with a detailed description of the trial. Pre-
liminary findings, which have been presented at a conference  [12] , 
show a better outcome for the combination treatment.
 The AD-COMBI study began after the termination of the 
MCI-COMBI-study. It assesses the 1-year efficacy and safety of a 
combination of galantamine and memantine versus galantamine 
alone. This is a 2-arm, randomized, double-blind, multicenter 
study. This study is still ongoing; however, recruitment is com-
plete (last patient was in by December 2007). In total, 233 patients 
were randomized. As the data clearing process for the last 16 sets 
of baseline data is not yet complete, the baseline data of 217 pa-
tients are presented in this report.
 The principle inclusion criteria for the AD-COMBI study were 
a clinical diagnosis of AD and an MMSE score of  6 15. Of the 233 
randomized patients, 2 received a diagnosis of mixed dementia, 
i.e. AD plus significant cerebrovascular changes. A detailed de-
scription of the trial will be published elsewhere.
 MCI patients of the DAP study who were found to have con-
verted to AD at a follow-up visit were given the option to discon-
tinue their enrolment in the DAP study and change to the AD-
COMBI study. Three patients accepted this offer. Furthermore, 
38 MCI patients from the DAP study changed to the MCI-COM-
BI study when this trial was started. In addition, a small number 
of patients (n = 3) who had taken part in the MCI-COMBI study, 
converted to AD during or after the study, and had not previ-
ously received galantamine and/or memantine were included in 
the AD-COMBI study.
 Multidimensional Phenotyping 
 Neuropsychological Assessment . The tests used for patient phe-
notyping are given in  table 4 .
 Routine MRI or CT Scanning . Each subject underwent an axi-
ally oriented T 1 -, T 2 - and FLAIR-sequence or a CT scan during 
the screening phase, which was clinically evaluated. In addition, 
semi-quantitative ratings of atrophy, infarct number and subcor-
tical white matter changes in predefined cortical and subcortical 
regions of both hemispheres were performed at each center.
 Structural Volumetric MRI . MRI scans were obtained on 1.5-
Tesla scanners. Siemens scanners (Siemens Sonata or Siemens 
Magnetom Vision) were used at 8 centers and Philips scanners 
(Philips Gyroscan and Philips Intera) at the remaining 4 centers. 
The 2 centers with the lowest recruitment rate did not enroll pa-
tients into MRI scanning. For standardization of MRI acquisition 
across centers, acquisition parameters were provided to all cen-
ters as a guideline. The phantom test of the American College of 
Table 4. Schedule of data acquisition
Screening part 1 Screening part 2 Baseline examination
Subjective Memory Decline Scale CDR ADAS-cog 
Baseline demographic factors Syndrome diagnosis Montgomery-Asberg Depression Rating Scale
Pre-existing and concomitant diseases Etiological diagnosis Free and Cued Selective Reminding Test
Medication/drugs (MCI or dementia diagnosis)
Laboratory examinations




Wisconsin Card Sorting Test
Frontal Assessment Battery
Neuropsychiatric Inventory
ACDS-MCI-ADL (Activities of Daily Living –
MCI Version), only for patients with MCI
ADCS-ADL (Activities of Daily Living –
AD Version), only for patients with AD
Risk factors 
Family history
Resource Utilization in Dementia
MRI – voxel-based morphometry
MRS 
CSF for neurochemical dementia diagnosis
Genetic testing
Wechsler Memory Scale Revised (logical
memory 1 and 2)
Consortium to Establish a Registry
for Alzheimer’s Disease –
Neuropsychological Battery
Clock-drawing test
Trail-making test (parts A and B)
Assessment of spontaneous speech
(Aachen Aphasia Test)
Physical examination
Informant Questionnaire on Cognitive
Decline in the Elderly
B-ADL (activities of daily living questionnaire)
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Radiology MRI Accreditation Program was conducted repeated-
ly at 11 sites of the DCN  [13] . Furthermore, a single volunteer, who 
travelled to each of the 11 centers, was investigated at each center. 
The results served to further increase the comparability of the 
scanning results between centers. MRI scans were conducted 
with a sagittal magnetization-prepared rapid gradient echo se-
quence on Siemens scanners, and with a 3D fast T 1 -weighted gra-
dient echo sequence on Philips scanners. At all centers, the rep-
etition time varied between 9.3 and 20 ms and echo time between 
3.93 and 4.38 ms. Hippocampal and amygdalar volumes were de-
termined for all scans  [14] .
 Proton MRS . Four centers (Bonn, Erlangen, Hamburg and 
Mannheim) participated in a single-voxel  1 H-MRS study of the 
left medial temporal lobe using 1.5-T scanners (Philips Gyroscan 
Intera, Siemens Magnetom Vision, Siemens Magnetom Sonata). 
Multicenter reproducibility was assured by using measurements 
of a human volunteer  [15] .
 Routine Clinical Chemistry Examinations. Clinical chemistry 
investigations were performed in the routine laboratories of the 
participating centers and interpreted with reference to the normal 
values of the respective laboratories.
 Apolipoprotein E   4 Genotyping . For DNA analysis, leukocyte 
DNA was isolated with the Qiagen blood isolation kit (Qiagen, 
Hilden, Germany). The apolipoprotein E   4 genotype was studied 
as previously described  [16] .
 Neurochemical Dementia Diagnostics . Standardized operating 
procedures (SOPs) for collecting, storing and shipping human 
body fluids were defined  [17] and implemented in the participat-
ing centers. Since the biomarkers (amyloid   peptides and, to a 
lesser extent, tau proteins) are sensitive not only to the storage 
conditions, but also to the plastic material of the test tubes  [18] , 
these SOPs took several aspects of sample collection and prepara-
tion into consideration. To avoid inter-laboratory imprecision of 
measurements  [19] , all samples were measured in 1 center (Erlang-
en). Based on our preliminary studies on biomarkers in AD and 
other dementias  [20–23] , we performed measurements of the 
‘classic’ biomarkers: A  x–40 (The Genetics Co., Zürich, Switzer-
land)  [24] , A  x–42 (The Genetics Co.)  [24] , A  1–42 (Innogenet-
ics, Ghent, Belgium)  [25] , Tau (Innogenetics)  [26] and p-Tau181 
(Innogenetics)  [20, 27] using established ELISAs in all available 
CSF samples. All samples were measured in duplicate and the 
means were used for further analysis.
 Further Variables . In addition, a range of further demograph-
ic, historical, laboratory and psychological data were acquired at 
screening and at baseline, and will be presented in follow-up pub-
lications: history and medical data: schooling, professional edu-
cation and achievement; medical and psychiatric history; family 
demographics and history of neuropsychiatric disease; medica-
tion and vitamin use; smoking and alcohol consumption; initial 
and current dementia and behavioral symptoms; resource utiliza-
tion parameters; general medical and neurological findings. For 
neuropsychological and ADL variables, see  table 4 .
 Ethical Considerations 
 The DAP study was approved by the Ethics Review Board of 
the Erlangen medical faculty (coordinating center) and by the 
Ethics Committees at each individual center, and was conducted 
in accordance with the Declaration of Helsinki. The MCI-COM-
BI and AD-COMBI studies were approved by the Ethics Review 
Board at the location of the principle investigator of the studies 
(Berlin) and by the Ethics Committees at each individual center, 
in compliance with the regulations of the German medical drug 
law. Patients initially received written and verbal information re-
garding the study during the screening visit, for which they gave 
informed consent. After screening, participants were requested to 
sign the consent form for performing additional diagnostic pro-
cedures and for participation in the treatment studies. Patients 
who gave informed consent to participate were then examined in 
a comprehensive clinical and neuropsychological assessment. In 
parallel, caregivers/informants agreed to fill out a caregiver-fo-
cused questionnaire.
 Data Collection 
 The data that were collected in the centers were transferred 
into a GCP-certified system (secuTrial 1.8 based on a central Or-
acle V9 database) via an internet-based remote data entry system. 
Data security and confidentiality were ensured by keeping iden-
tification data and clinical data separately, linked only by center-
specific ID codes (pseudonyms). This pseudonymization was per-
formed in the study centers, according to the TMF generic data 
protection concept B  [28] . During the entire process of data cap-
ture, verification and analysis, clinical data were identified and 
linked using the pseudonyms. In addition to the data stored in the 
central database, each center kept a copy of its data in electronic 
or written form. MR images were saved in standardized format, a 
copy being kept both at the study center and at the DCN reference 
center for MR analysis. Neuropsychological tests and demo-
graphic data were stored in paper-based case report forms and 
case files, and were transferred from there to the electronic DCN 
database. Likewise, standard biochemical laboratory data were 
kept in a laboratory database and in a printed version at each study 
center, and were transferred to the DCN database.
 Multimodal Biomaterial and Databank 
 Blood, serum and CSF samples were collected in polypropyl-
ene vials with a unique 14-digit 2-dimensional barcode. The 
 vials were then placed and stored in a 96-well format plastic 
 container in predefined positions. This system enabled system-
atic storage of several thousand aliquots collected by the par-
ticipating centers, and significantly improved management of 
the samples.
 Clinical, neurochemical and imaging data were transferred to 
a single databank. This enabled the linkage of different types of 
data from individuals or selected subject groups, as identified by 
unique pseudonyms. Access to these linked data is granted by the 
DCN steering committee.
 Quality Control and Methods against Bias 
 Neuropsychological and related assessments were performed 
by experienced physicians and psychologists. Rater trainings 
were conducted beforehand. The clinical and neuropsychological 
evaluation was supported by the use of clinical DCN SOPs  [29] . 
Furthermore, a telephone hotline was available for the center co-
workers to answer ad hoc questions. Neuropsychological raters 
were blinded for MRI and CSF results, and vice versa. Reasons for 
dropout were investigated and documented. In order to minimize 
non-response and missing data, patients were reminded of up-
coming follow-up visits, and, if necessary, called at home. SOPs 
for neurochemical dementia diagnostics were developed  [17] and 
transmitted to the participating centers in written form. This se-
cured rigorously monitored large-scale preanalytical sample han-
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dling. A barcode-based storage system assured fast and precise 
access to a required body fluid sample.
 Routine MRI and research MRI data acquisition were per-
formed in a standardized fashion  [13] by the local neuroradiology 
departments. Multicenter reproducibility of volumetric MRI and 
MRS was assured by a technical phantom and a human volunteer 
 [13, 15] . The measurements of biochemical and genetic markers, 
and the processing of imaging data were performed in 1 reference 
center to avoid center effects (neurochemical dementia markers: 
Erlangen; apolipoprotein E genotyping: Bonn; quantitative hip-
pocampal and corpus callosum volumetry: LMU Munich; MRS: 
Bonn). As an incentive for timely and complete delivery, the par-
ticipating centers obtained capitation fees for including patients 
and data into the study. Fees were calculated according to the 
completeness of clinical data, imaging studies and biological ma-
terials, i.e. only costs of data and materials that were successfully 
shipped to the reference centers were reimbursed.
 Data handling was conducted according to the concept estab-
lished by the TMF project (Telematic Platform for Medical Re-
search Networks). Data quality in the central database was as-
sured by several measures: (1) direct plausibility checks during 
data entry, where applicable, (2) queries were sent to the centers 
about conspicuous or incongruent data entries, as identified au-
tomatically by a set of checking rules; missing data were not re-
placed in the DAP study, and handling of missing data in the 
clinical trial will be described in the respective publication, (3) the 
algorithm of Morris  [8] was applied centrally to determine the 
overall CDR score, based on the ratings of the 6 categories that 
were provided by the centers, and (4) volumetric MRI datasets 
were transferred into the central database where a rigorous com-
pleteness check was performed. Finally, the whole study was su-
pervised by an external advisory board.
 Statistical Analysis 
 Analyses of the baseline data set presented here were per-
formed using descriptive statistics, 2-sided t tests, non-paramet-
ric tests and calculation of Pearson’s correlations, as appropriate. 
The statistical analyses were performed with SPSS for Windows 
(version 15.0, Chicago, Ill., USA) and SAS software (version 9.3, 
Cary, N.C., USA). The data presented here are based on an export 
of the databank from November 2007.
 Results 
 From May 2003 until November 2007, 2,113 subjects 
passed the screening examinations and were assigned to 
1 of the relevant diagnostic groups ( fig. 2 ;  tables 1 ,  5 and 
 6 ). There were 1,870 patients (790 dementia, 1,080 MCI 
patients) and 243 control subjects (201 healthy, 42 dis-
eased controls). Of note, the actual number of patients is 
minimally lower than the number of ‘cases’, because a few 
patients who were first referred to the DAP study later 
switched to one of the clinical trials (MCI-COMBI or 
AD-COMBI). These patients were handled in the data-
base as if they were new subjects. Upon entering one of 
the drug trials, patient screening was repeated and all 
data refreshed.
 Dementia cases were further subdivided into AD (n = 
577), FTD (n = 51), VD (n = 35), mixed AD/VD (n = 72), 
Lewy body dementia (n = 8), Parkinson dementia (n = 5), 
Huntington’s disease and corticobasal degeneration (n = 
2 each), progressive supranuclear palsy and multisystem 
atrophy (n = 1 each), other (n = 11) and undetermined
(n = 25). Recruitment across memory clinics was uneven 
( table 1 ). Selected demographic and neuropsychological 
characteristics of the main groups and subgroups are 
shown in  table 5 . Additional variables not presented here 






























Age at entry, years 68.9 66.9 71.6 71.9 72.4 75.9 64.3 69.1 66.0 64.4
Schooling, years 9.3 9.5 9.1 9.2 8.4 8.5 9.0 9.2 10.2 9.2
Male, % 48.6 53.8 41.4 37.6 51 44 51 60 44 52
CDR (sum of boxes) 3.0 1.6 4.9 4.8 4.4 5.0 5.4 5.1 0.03 0.06
MMSE score 25.4 27.1 (14) 23.1 (24) 22.9 24.2 23.4 23.7 23.5 28.5 29.0
ADAS-cog (sum) 14.8 11.5 (85) 19.4 (58) 19.3 18.5 20.3 20.9 18.4 – –
BAYER ADL (mean) 3.3 2.3 (85) 4.6 (84) 4.5 4.9 5.0 4.9 5.0 1.1 1.1
NPI (sum) 6.3 5.0 (275) 7.8 (94) 6.8 7.3 9.8 14.6 10.3 0.5 –
MADRS (sum) 7.7 7.8 (89) 7.7 (66) 7.1 9.7 7.7 9.6 11.0 2.4 –
FBI (sum) 10.3 7.8 (61) 13.8 (78) 12.5 16.3 13.3 23.7 16.7 0.6 0.4
Figures in parentheses show the number of subjects with missing data. NPI = Neuropsychiatric Inventory; MADRS = Montgomery-Åsberg Depres-
sion Rating Scale; FBI = Frontal Behavioral Inventory.
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are listed in the ‘Methods’. The assignment of the subjects 
to the 3 studies (DAP, MCI-COMBI and AD-COMBI) 
and the residual ‘screening only’ category is shown in  fig-
ures 1 and  2 .
 Comparisons between subgroups defined by disease 
status show that mean age was significantly higher in 
AD, VD and mixed AD/VD patients compared to MCI 
patients (t tests, p  ! 0.001). Mean age was significantly 
lower in FTD patients compared to other dementia pa-
tients (t test, p  ! 0.001). Mean values for MMSE and 
CDR sum of boxes showed only minor variations in the 
4 principle dementia subgroups ( table 1 ). The highest 
achieved educational level, as determined by a 6-step 
ordinal scale, was significantly higher in control sub-
jects (healthy and diseased controls) compared to de-
mentia and MCI patients (Kruskal-Wallis test, p  ! 0.001, 
data not shown). A comparison of MCI and dementia 
patients showed a slightly lower mean education in de-
mentia patients (years in school, Mann-Whitney U test, 
p  ! 0.001).
 In total, 599 CSF samples were acquired (298 MCI, 259 
dementia, 42 diseased controls), as well as approximately 
1,700 MRI and 500 MRS data sets.
 Violations of inclusion criteria were noted in a small 
minority of patients, i.e. 26 patients were younger than 50 
years of age, 31 patients in the DAP study had MMSE 
scores below 20, and 4 participants of the AD-COMBI 
trial had MMSE scores below 15. These cases were re-
tained in the study, and were included in the analysis fol-
lowing an intention-to-treat policy.
 Flow Chart 
 The 2,113 subjects who were included in the study 
were assigned to 1 of 4 tracks, as shown in  figure 1 . Pa-
tients in the long-term observational study (DAP study) 
consented to participate in annual follow-up examina-
tions. Patients in MCI-COMBI (MCI only) and AD-
COMBI (AD only) were included in 2 randomized and 
controlled clinical trials which compared the efficacy
of combined galantamine/memantine treatment with 
Table 6. Comparison of key demographic and key neuropsychological characteristics (mean values) of patients who participated in 
















AD patients in 
AD-COMBI
(n = 215)
Age at entry, years 66.9 66.6 67.7 71.9 71.8 72.1
Schooling, years 9.5 9.5 9.2 9.2 9.2 9.0
Male, % 53.81 55.1 51.0 37.62 40.8 33.0
CDR (sum of boxes) 1.6 1.7 1.4 4.8 4.7 4.9
MMSE score 27.1 27.2 27.1 22.9 23.4 22.1
ADAS-cog (sum) 11.5 11.5 11.3 19.3 19.1 19.6
1 Significantly higher proportion of men in the group of MCI patients; p = 0.013 (2 test).
2 Significantly higher proportion of women in the group of AD patients; p < 0.001 (2 test).
MMSE CDR (sum of boxes) ADAS-cog FBI B-ADL
CDR (sum of boxes) –0.33**
ADAS-cog –0.55** 0.27**
FBI –0.08 0.34** 0.11
B-ADL –0.28** 0.47** 0.23** 0.46**
Age –0.08 0.10** 0.13** –0.04 0.15**
FBI = Frontal Behavioral Inventory. ** p < 0.01, 2-sided.
Table 7. Pearson correlations between 
main neuropsychological and descriptive 
variables in the group of all dementia 
patients (n = 790)
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galantamine monotherapy and with placebo treatment
in MCI, and galantamine/memantine treatment with
galantamine monotherapy in AD.
 Table 6 shows key demographic and neuropsychologi-
cal characteristics of MCI and AD patients who took part 
in the DAP study versus those who took part in the clinical 
trials MCI-COMBI and AD-COMBI. In the group of MCI 
patients, the proportion of men was significantly higher
(p = 0.013;   2 test), while there was a higher proportion of 
women in the group of AD patients (p  ! 0.001;   2 test).
 Correlational Analyses 
 An exploratory correlation analysis between the prin-
ciple neuropsychological and descriptive values was per-
formed within the group of all dementia patients (n = 
790;  table 7 ).
 Discussion 
 The DCN formed an academic research network 
among 14 memory clinics at German university hospi-
tals. All patients in this study were uniformly evaluated 
using a defined set of clinical, neuropsychological, bio-
chemical and imaging tests and followed up longitudi-
nally. A longitudinal clinical database was established 
with the data obtained from these patients, including 
neuropsychological and clinical variables, a biochemical 
database involving blood and CSF samples, an imaging 
database involving a volumetric data set using a FLAIR 
sequence, and a DNA bank.
 The largest diagnostic subgroup is represented by MCI 
patients. This may be partly related to an inclination of 
German general practitioners to refer early-stage patients 
with a self-reported mild cognitive decline to a university 
memory clinic, and may also be due to the active recruit-
Table 8. Comparison of large prospective multicenter studies in MCI
DCN (MCI patients
in DAP study)
Pre-AL ACCORD ITINAD DESCRIPA ADNI
Sample size (MCI subjects) 813 251 466 269 883 394
Recruitment period 2003–2007 2001–2002 1997–1999 unknown 2003–2006 2004–2007
Inclusion criteria
MMSE cutoff no >29 no ‘abnormal’ no <24
CDR or equivalent score = 0.5 yes no no no no yes
Test impairment yes yes no yes no yes
Informant required yes yes no no no yes
Cutoff score for age >50 >58 none 50–80 >55 55–90
Exclusion criteria
Detailed exclusion criteria for 
potential causes of cognitive
impairment or dementia other 
than neurodegenerative or vas-
cular disease
yes yes no yes yes yes
Characteristics of the cohort
Mean age, years 66.6 72 65 70.3 70.3 74.7
Education (mean), years 9.5 (schooling years) unknown 12.8 7.9 10.4 15.7
Females, % 45 60 55 57 57 36
Apolipoprotein E 4 carriers, % will be reported in 
future publications
unknown 40 unknown 41 unknown
Biomaterials collected
Serum yes no no no yes yes
Volumetric MRI yes no no no yes yes
MRS yes no no no no no
CSF yes no no no yes yes
FDG-PET or SPECT no yes no no no yes
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ment of patients with mild cognitive disturbances. The 
high proportion of MCI patients, and the focus on mild-
stage dementia may explain the low overall mean average 
age of 68.5 years.
 In our cohort, the observed spectrum of dementia eti-
ologies shows a strong preponderance of AD cases (73%). 
This proportion is slightly higher than the estimated per-
centage of AD among all causes of dementia  [30] . A po-
tential reason may be that dementia cases with early 
physical (neurological) symptomatology are underrepre-
sented in the present sample, most likely due to a referral 
bias (i.e. most collaborating memory clinics are affiliated 
with psychiatric university hospitals, while dementia cas-
es with movement disorders or vascular disorders tend to 
be referred to neurological departments). The second-
largest subgroup of demented patients was the one in-
cluding patients with FTD (6.5%).
 The degree of cognitive impairment, as assessed by the 
MMSE score, was 4 points lower in dementia patients 
than in MCI patients (23.1 vs. 27.1). Mean age was 4.7 
years lower in MCI than in demented patients, which may 
partly be explained by the delay between onset of cogni-
tive impairment and conversion to dementia. It is also 
likely that some MCI patients suffered from a non-or-
ganic or non-progressive disease, which will be clarified 
by analyzing the follow-up data.
 Participants in the AD-COMBI study had a mean 
MMSE score of 22.1 (inclusion criterion: MMSE score 
 6 15), while the mean MMSE score was 23.4 (inclusion 
criterion: MMSE score  6 20) for participants of the long-
term observational DAP study. Otherwise, cognitive and 
demographic data of AD patients in the DAP and AD-
COMBI studies were closely matched ( table 6 ).
 The CDR score of dementia, as determined centrally 
by the CDR algorithm, was 0.5 in 253 patients who re-
ceived a clinical diagnosis of dementia. This discrep-
ancy between CDR score and diagnosis of syndrome 
can be explained by the fact that the clinical diagnosis 
of dementia was made by a team of experts at each cen-
ter in consideration of the whole spectrum of symp-
toms, which is not entirely assessed by the 6 categories 
of the CDR. Probably more importantly, the local inves-
tigators tended to diagnose dementia when 1 or 2 ‘box-
es’, i.e. domains, in addition to memory were rated 1. 
Remarkably, the Washington algorithm rates the overall 
CDR as ‘0.5’ even when 3 domains including memory 
are rated 1, and the other 3 are 0.5. The experience that 
we had here is relevant to studies, e.g. drug trials that 
employ the CDR as the principle criterion for conver-
sion to dementia. The investigators of this study will an-
alyze and describe the limitations of the CDR in a sub-
sequent publication.
 As expected, the analysis of correlations between key 
neuropsychological variables ( table 7 ) showed a substan-
tial inverse correlation between ADAS-cog and MMSE 
scores. The overall degree of dementia severity, as as-
sessed by the CDR sum of boxes, showed a substantial 
correlation with the B-ADL score, but less so with ADAS-
cog and MMSE scores. This is explained by the mode of 
CDR assessment, which is based on patients’ competence 
in daily living. Likewise, the Frontal Behavioral Inven-
tory score was correlated with CDR sum of boxes and B-
ADL scores, but unrelated to MMSE and ADAS-cog.
 For the key variables presented in  table 5 , the propor-
tion of missing data was generally low and tolerable, i.e. 
 ! 2% for dementia patients and 0–8% for MCI patients.
 Strengths of the DCN Platform and Studies 
 A network of research-oriented university-based 
memory clinics was set up for standardized assessment 
of MCI, early dementia and controls in longitudinal ob-
servational studies and clinical trials. An integrated 
structure to capture patient data and to establish tissue 
and DNA banks for diagnostic and therapeutic studies 
in dementia and MCI were developed. Patients and con-
trols were thoroughly phenotyped. A rigorous procedure 
for standardized preanalytical sample handling of bio-
logical fluid samples was implemented. This research in-
frastructure was supplemented by an integrated clinical 
databank including data from patients with dementia 
and MCI (covering neuropsychological, neuroimaging, 
neurochemistry and genetics), supported by study-spe-
cific comprehensive clinical research forms. Currently, 
the DCN biomaterial bank represents one of the largest 
prospectively collected sets of samples from subjects 
with MCI and early dementias. With the samples col-
lected in the biomaterial bank, recently introduced ana-
lytical technologies (e.g. SELDI-TOF-MS, surface-en-
hanced laser desorption-ionization time-of-flight mass 
spectrometry; DIGE TM , differential gel electrophoresis; 
and multiplexing) can be promptly tested with regard to 
their potential usefulness in neurochemical dementia 
diagnostics. A core achievement is the creation of the 
methods for multicenter neurochemical dementia diag-
nostics, volumetric MRI and MR spectroscopy. They en-
able the determination of the negative and positive pre-
dictive values of markers for the conversion of MCI to 
dementia using a multiparameter approach including 
clinical, neuropsychological, neurochemical and neuro-
imaging data.
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 The DCN consortium has been instrumental in im-
proving the German dementia research infrastructure by 
creating a platform of centers for future studies, e.g. up-
coming government-funded trials on the disease-modi-
fying effect of simvastatin in MCI, on the effects of a be-
havioral cognitive therapy program for coping with de-
mentia, and on the influence of physical activity on 
cognition in patients with mild Alzheimer’s dementia. 
From a worldwide perspective, the DCN-DAP study is 
one of the large prospective studies on MCI and mild de-
mentia. The SOPs that were developed in the DAP study 
have been adopted by other large clinical studies, e.g. the 
North American Alzheimer’s Disease Neuroimaging Ini-
tiative (ADNI) study.
 Limitations 
 The study was less successful than hoped in recruiting 
diseased control subjects, this was mainly due to the late 
start of recruitment within the funding period. The com-
position of dementia and MCI cases is not entirely repre-
sentative due to the referral bias discussed above. Al-
though every attempt was made to attain complete data-
sets and a rigorous data quality control process was 
installed, some data are missing. This is, however, mostly 
in the range of well below 10% per incomplete dataset. In 
the DAP study, data monitoring was performed centrally, 
without any onsite monitoring. As noted above, the MCI-
COMBI study was not completed according to plan. Due 
to the long time lag between study initiation and comple-
tion, several advances in diagnostic criteria could not be 
implemented. Potential discrepancies between old and 
new diagnostic criteria will be analyzed post hoc and 
published separately, e.g. regarding criteria for vascular 
dementia, FTLD or MCI subtypes.
 Comparison with Other Longitudinal Studies 
 The data on the DAP study can be compared with sev-
eral other clinic-based longitudinal cohort studies, i.e.
the European DESCRIPA study  [31] , the Italian Interdis-
ciplinary Network on Alzheimer’s disease (ITINAD) 
study  [32] , the French Pre-AL study  [33] , the Canadian 
ACCORD study  [34] , the AddNeuroMed (not published 
yet) and the (ADNI; www.adni-info.org). All of these 
studies are longitudinal multisite observational studies of 
subjects with MCI, some also include healthy elderly sub-
jects as normal controls. These studies varied consider-
ably with respect to sample size, inclusion and exclusion 
criteria and primary aims. Some of these studies, such as 
the European DESCRIPA study and the Pre-Al study in 
France, aimed to investigate markers of predementia AD, 
the prospective ITINAD-study investigated MCI patients, 
while other studies were not designed for this purpose,
e.g. the ACCORD study in Canada. The ADNI, which is 
the most recent of these studies, used the German DCN 
study as a template and is aiming primarily at: (1) collect-
ing data to establish a brain imaging and biomarker data-
base, (2) determining the optimum methods for acquiring 
and processing images for clinical trials, (3) developing 
‘standards’ for imaging and biomarker acquisition in de-
mentia diagnosis, and (4) ‘validating’ imaging and bio-
marker data by correlating them with behavioral and clin-
ical data to facilitate trials on new AD therapies.
 A summary of the inclusion and exclusion criteria and 
the patient characteristics of these studies are shown in 
 table 8 . The sample size of MCI patients recruited in these 
studies varied from 251 to 883, and mean age varied from 
65 to 74.7 years. All earlier studies used less restrictive 
clinical or neuropsychological inclusion criteria than 
those implemented in the German DCN and the ADNI 
studies. The collection of biomaterials and the analysis of 
biomarkers were most extensive in the DCN and the 
ADNI studies.
 It is clear from  table 8 that the sample of MCI patients 
collected in earlier studies, i.e. Pre-AL, ACCORD and 
ITINAD, or the study with the broadest set of inclusion 
criteria, i.e. DESCRIPA, will differ strongly from the MCI 
patient sample in the DCN and the ADNI studies. In ac-
cordance with the primary aims of the latter 2 studies, it 
is likely that the DCN and the ADNI cohorts will have 
the highest prevalence of predementia AD patients in 
their patient sample, which is prerequisite to the develop-
ment, evaluation and comparison of various markers. 
The sample size in the DCN cohort is approximately 
twice the size of the ADNI sample, while both have a sim-
ilar CSF sampling rate.
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